Evotec Investor Day Presentation Deck

evotec PAGE 32 Interferon pathway stimulation compared to Pegasys 3,000 2,500 2,000 1,500 1,000 0,500 0,000 0,3 1 Parental Ab Abk77 3 HAH HA ng/ml T Stimulate interferon pathway and agonise CD40 EVT895: A potent biologics antiviral - Bifunctional molecule 1 10 30 100 300 1000 CD40 agonism compared to CD40 agonistic antibody O.D 2,500 2,000 1,500 1,000 0,500 0,000 1000'0 100'0 0,01 Abk 77 Pegasys ng/ml 100 Hbe release: Comparison with Pegasys (donor 2) Late pre-clinical development; Phase I in 2021 (e) Hbe release ( 160,0 140,0 120,0 100,0 80,0 60,0 40,0 20,0 0,0 E MOI 500 0,0000001 HA 0,00001 SANOFI 0.0001 Concentration (nM) 0.10 Abk77 -Pegasys

View entire presentation